To assess this potential, we first designed SNIPRs with extracellular domains (ECDs) incorporating scFvs derived from a set of antibodies against the broadly tumour-associated cytokines TGFβ (ref. 5) and vascular endothelial growth factor-α (VEGF; ref. 17). The gene discussed is TGFB1; the disease is neoplasm.